Lantern Pharma has recently introduced an innovative AI-powered module within its RADR(R) platform, designed to assess the synergy and patient response to combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). This development is significant as it leverages genomic, transcriptomic, and clinical data to predict treatment outcomes, supporting the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. The module's predictive algorithm was informed by a comprehensive review of 221 clinical trials, highlighting the potential of non-PARP DDRi combinations with DNA-damaging agents in specific cancer subtypes.
The integration of this technology into Lantern’s RADR(R) platform represents a pivotal step forward in the use of artificial intelligence and machine learning in oncology drug development. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, according to Lantern’s analysis, the timing of this launch underscores the growing importance of AI in identifying effective treatment combinations. The company is currently exploring licensing opportunities to commercialize the module for broader oncology use, which could significantly impact the way cancer treatments are developed and personalized for patients.
For more information on Lantern Pharma and its advancements in AI-driven oncology solutions, visit https://ibn.fm/LTRN. This development not only highlights Lantern Pharma's commitment to redefining cancer treatment through technology but also sets a new standard for the integration of AI in drug development processes.
